Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
12.81
0.00 (0.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Design Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Design Therapeutics stock have an average target of 15.25, with a low estimate of 14 and a high estimate of 18. The average target predicts an increase of 19.05% from the current stock price of 12.81.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 16, 2026.
Analyst Ratings
The average analyst rating for Design Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 1 | 2 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $15 | Strong Buy | Initiates | $15 | +17.10% | Mar 16, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $13 → $14 | Buy | Maintains | $13 → $14 | +9.29% | Mar 10, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $18 | Buy | Initiates | $18 | +40.52% | Jan 7, 2026 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $7 → $14 | Hold → Buy | Upgrades | $7 → $14 | +9.29% | Dec 3, 2025 |
| RBC Capital | RBC Capital | Hold → Buy Upgrades $6 → $13 | Hold → Buy | Upgrades | $6 → $13 | +1.48% | Nov 20, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.43
from -1.22
EPS Next Year
-1.69
from -1.43
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.21 | -1.45 | ||||||
| Avg | -1.43 | -1.69 | ||||||
| Low | -1.64 | -2.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.